🔴 Telix Pharmaceuticals is trading 7.17% down; no clear catalyst identified

Telix Pharmaceuticals is trading at A$14.63, down 7.17%, with no clear catalyst verified.

• Q3 revenue was US$245 million, up 19% year over year; Telix reaffirmed FY2026 revenue and other income above US$1 billion.
• Telix narrowed its FY2026 R&D spending outlook to US$240–260 million. Available reporting does not link the announcement to the decline, and positive sector context does not explain the move.